<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann S LaCasce, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrea K Ng, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hodgkin lymphomas (HL; formerly called Hodgkin's disease) are lymphoid neoplasms in which malignant Hodgkin/Reed-Sternberg (HRS) cells are admixed with a heterogeneous population of non-neoplastic inflammatory cells.</p><p>HL is divided into two major categories, based on morphology and immunophenotype  (<a class="graphic graphic_table graphicRef76591" href="/z/d/graphic/76591.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Classic HL (cHL) comprises 90 percent of HL and is further subtyped according to pathologic features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nodular sclerosis cHL (NSCHL)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mixed cellularity cHL (MCCHL)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocyte rich cHL (LRCHL)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocyte depleted cHL (LDCHL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodular lymphocyte predominant HL (NLPHL)</p><p></p><p>Evaluation, diagnosis, and pretreatment evaluation of cHL is presented here.</p><p>Epidemiology and risk factors; pathogenesis; pretreatment evaluation, staging, and prognosis; and an overview of treatment of cHL are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma"</a>.)</p><p></p><p></p><p>Clinical manifestations, diagnosis, and treatment of nodular lymphocyte-predominant HL are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging"</a> and  <a class="medical medical_review" href="/z/d/html/4732.html" rel="external">"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H78183236"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H3542771661"><span class="h2">Disease tempo</span><span class="headingEndMark"> — </span>cHL generally progresses slowly, but the tempo of disease is variable. Lymphadenopathy, constitutional symptoms, fatigue, and/or pruritus are often recognized to have begun weeks to months before the patient is evaluated for cHL. Mediastinal masses can be quite large before causing chest discomfort or respiratory symptoms, which is consistent with a slow rate of growth.</p><p class="headingAnchor" id="H1444841395"><span class="h2">Typical presentations</span><span class="headingEndMark"> — </span>Most patients with cHL present with asymptomatic lymphadenopathy or a mass on chest radiograph [<a href="#rid1">1</a>]. Constitutional symptoms ("B" symptoms; ie, fever, night sweats, or unintended weight loss) are present in approximately 40 percent of cases. </p><p>In a minority of cases the clinical presentation of cHL is relatively nonspecific or atypical. (See <a class="local">'Less common presentations'</a> below.)</p><p class="headingAnchor" id="H2571368515"><span class="h3">Lymphadenopathy</span><span class="headingEndMark"> — </span>Lymphadenopathy is detectable in more than two-thirds of patients with cHL at presentation  (<a class="graphic graphic_figure graphicRef55422" href="/z/d/graphic/55422.html" rel="external">figure 1</a>), and the involved lymph nodes are usually nontender and have a firm, rubbery consistency. </p><p>The neck is the most common site of involvement, as 60 to 80 percent of patients have enlarged cervical and/or supraclavicular nodes  (<a class="graphic graphic_table graphicRef51115" href="/z/d/graphic/51115.html" rel="external">table 2</a>) [<a href="#rid2">2,3</a>]. Enlarged axillary nodes are found in approximately 30 percent and inguinal nodes in 10 percent of patients. Although they are not detectable on physical examination, mediastinal nodes are involved in 50 to 60 percent and retroperitoneal nodes in 30 percent of patients. Infradiaphragmatic lymphadenopathy alone is uncommon, occurring in &lt;10 percent of patients. </p><p>Dissemination generally proceeds from a single lymph node region to adjacent lymph nodes via lymphatic channels before involving more distant or nonadjacent sites and organs  (<a class="graphic graphic_figure graphicRef55422" href="/z/d/graphic/55422.html" rel="external">figure 1</a>) [<a href="#rid4">4-6</a>]. It is likely that cHL can spread via the thoracic duct, possibly in either direction, without clinical enlargement of mediastinal nodes. Noncontiguous spread and/or hematologic dissemination are uncommon, but are more often encountered in immunosuppressed patients (eg, HIV/AIDS), as discussed below. (See <a class="local">'Less common presentations'</a> below.)</p><p class="headingAnchor" id="H3779816763"><span class="h3">Mediastinal mass</span><span class="headingEndMark"> — </span>Discovery of a mediastinal mass on routine chest radiograph is another common presentation of cHL; the mass may be asymptomatic or associated with cough, shortness of breath, or retrosternal chest pain. Pericardial or pleural effusions are uncommon, except in patients with bulky mediastinal disease, and presentation with superior vena cava syndrome is rare. (See  <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome"</a>.)</p><p>Among patients with early stage cHL, large mediastinal adenopathy is an adverse prognostic factor that influences treatment decisions, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma", section on 'Favorable early stage'</a>.)</p><p class="headingAnchor" id="H78183315"><span class="h3">B symptoms</span><span class="headingEndMark"> — </span>B symptoms specifically refers to fever, night sweats, or weight loss in association with lymphoma. B symptoms generally accompany lymphadenopathy, but patients occasionally present with B symptoms alone. The presence of B symptoms varies with disease stage; B symptoms are present in &lt;20 percent of patients with stage I/II cHL and up to half of patients with advanced disease. </p><p>B symptoms are formally defined as follows [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever – Persistent temperature &gt;38°C (&gt;100.4°F)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sweats – The presence of drenching night sweats</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss – Unexplained loss of &gt;10 percent of body weight over the past six months</p><p></p><p>Other symptoms (eg, fatigue, pruritus, alcohol-associated pain) are not considered B symptoms.</p><p>Fever that accompanies cHL is often more noticeable in the evening and becomes more severe and continuous with time. Pel-Ebstein fever refers to an uncommon but characteristic presentation in which fever cyclically increases and then decreases over a period of one to two weeks [<a href="#rid8">8</a>]. </p><p>The presence of B symptoms is an adverse prognostic feature that influences treatment decisions, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma", section on 'Favorable early stage'</a>.)</p><p class="headingAnchor" id="H245848538"><span class="h3">Pruritus</span><span class="headingEndMark"> — </span>Pruritus occurs in approximately 10 to 15 percent of patients at presentation and can precede the diagnosis of cHL by months or even a year or longer [<a href="#rid9">9</a>]. Pruritus is typically generalized and occasionally is severe enough to cause intense scratching and excoriations. Pruritus is <strong>not</strong> considered a B symptom. </p><p class="headingAnchor" id="H646720224"><span class="h2">Less common presentations</span><span class="headingEndMark"> — </span>Less common or atypical presentations of cHL include extranodal disease, noncontiguous spread to multiple nodal groups, bone marrow or liver involvement, and isolated laboratory abnormalities. Atypical presentations can be seen in any patient, but are more common in individuals with human immunodeficiency virus (HIV) infection or other immunosuppressed patients [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/4750.html" rel="external">"HIV-related lymphomas: Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Examples of less common clinical presentations of cHL include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alcohol-associated pain</strong> – Rarely, patients with cHL complain of severe pain following alcohol ingestion. The pain typically begins within minutes of ingestion of even a small amount of alcohol [<a href="#rid11">11</a>]. Alcohol-associated pain usually occurs at sites of bony involvement, but it may also occur at sites of lymphadenopathy. While alcohol-associated pain is uncommon (&lt;10 percent) and has no prognostic significance, it is highly specific for a diagnosis of cHL. The mechanism of alcohol-associated pain is unknown. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong> – Liver involvement may be manifest as abnormal liver function tests or as abdominal pain, nausea, anorexia, other nonspecific findings. However, liver involvement as the sole presenting manifestation of cHL is uncommon. In one study, liver involvement was found in approximately 5 percent of 285 patients who later underwent staging laparotomy [<a href="#rid12">12</a>]. In another study, only 6 of 421 consecutive patients who were diagnosed with HL presented with liver abnormalities that led to a liver biopsy and subsequent diagnosis [<a href="#rid13">13</a>]. Rarely, fulminant liver failure can also occur as a paraneoplastic manifestation without hepatic infiltration [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other intra-abdominal disease</strong> – Retroperitoneal lymphadenopathy may cause flank discomfort or pain, but isolated infradiaphragmatic lymphadenopathy (ie, without other involved nodal regions) is uncommon. Some patients experience abdominal swelling due to splenomegaly, hepatomegaly, or rarely ascites, but involvement of the gastrointestinal tract by cHL is rare. Extensive intra-abdominal disease can cause ureteral obstruction or compression of renal veins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin lesions</strong> – Skin lesions that have been described in association with cHL include ichthyosis, acrokeratosis (Bazex syndrome), urticaria, erythema multiforme, erythema nodosum, necrotizing lesions, hyperpigmentation, and skin infiltration [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone/bone marrow involvement</strong> – Bony involvement at presentation is uncommon, but it is suggested by a history of bone pain or elevation of serum alkaline phosphatase or calcium. Bone marrow infiltration may be manifest as unexplained cytopenias or bone pain. Bone marrow involvement by cHL at presentation is associated with advanced clinical stage; it has been reported in up to 6.5 percent of all patients with newly diagnosed cHL, but in virtually none with early stage disease [<a href="#rid17">17-21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic findings</strong> – Direct involvement of the central nervous system (CNS) by cHL is rare (eg, ≤0.5 percent at presentation) [<a href="#rid22">22-25</a>]. Several paraneoplastic syndromes, including cerebellar degeneration, chorea, neuromyotonia, limbic encephalitis, subacute sensory neuropathy, subacute lower motor neuropathy, and the stiff person syndrome have been described in association with cHL [<a href="#rid26">26-36</a>]. (See  <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a> and  <a class="medical medical_review" href="/z/d/html/15822.html" rel="external">"Paraneoplastic cerebellar degeneration"</a> and  <a class="medical medical_review" href="/z/d/html/5131.html" rel="external">"Stiff-person syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrotic syndrome</strong> – Nephrotic syndrome can occur as a paraneoplastic syndrome in patients with early stage cHL. The usual pathologic pattern is minimal change disease, but focal segmental glomerulosclerosis, can also occur [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults", section on 'Malignancies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory abnormalities</strong> – A variety of laboratory abnormalities can occur in patients with cHL. Some of these abnormalities (eg, anemia, lymphopenia, leukocytosis, hypoalbuminemia) are associated with adverse outcomes, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma", section on 'International Prognostic Score (IPS)'</a>.)</p><p></p><p class="bulletIndent1">Examples of laboratory findings at presentation include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypercalcemia</strong> – Hypercalcemia is usually due to increased production of calcitriol (1,25-dihydroxyvitamin D3) and less commonly is caused by direct bony involvement [<a href="#rid39">39,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/841.html" rel="external">"Hypercalcemia in granulomatous diseases"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anemia</strong> – Anemia can be due to diverse causes, including bone marrow replacement by cHL, hypersplenism, anemia of chronic inflammation, and rarely may be due to a Coombs-positive hemolytic anemia, with or without immune thrombocytopenia [<a href="#rid41">41,42</a>]. (See  <a class="medical medical_review" href="/z/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eosinophilia</strong> – Eosinophilia is relatively common in HL and is caused by production of chemokines (eg, interleukin-5, eotaxin) that recruit eosinophils and/or stimulate eosinophil production [<a href="#rid43">43,44</a>]. (See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – Other laboratory abnormalities may include leukocytosis, thrombocytosis, lymphopenia, and hypoalbuminemia. Some of these findings are associated with inferior prognosis, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H1342975505"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H2115629728"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The history should evaluate the presence, duration, and extent of lymphadenopathy; cough or other respiratory symptoms; and unexplained fever, sweating, weight loss, pruritus, and alcohol-induced pain. It is important to document a personal history of previous malignancy (including other lymphomas); prior treatment with chemotherapy or radiotherapy; human immunodeficiency virus (HIV) infection or other immunosuppressive condition; or a family history of lymphoproliferative, myeloproliferative, or other malignancies.</p><p>Physical examination must evaluate all accessible lymphoid regions, including the size, number, and regions of lymph node enlargement, and the presence of splenomegaly or hepatomegaly  (<a class="graphic graphic_figure graphicRef55422" href="/z/d/graphic/55422.html" rel="external">figure 1</a>). Waldeyer's ring (tonsils, base of the tongue, nasopharynx) should be examined, especially in patients with adenopathy in the neck.</p><p>Aspects of the history and physical examination that are required for pretreatment evaluation and staging of cHL are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma", section on 'History and physical examination'</a>.)</p><p class="headingAnchor" id="H832188628"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Laboratory studies for all patients should include: </p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) with differential count and erythrocyte sedimentation rate (ESR)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum chemistries, including electrolytes, liver and renal function tests, and albumin</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV testing (see  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection", section on 'Preferred approach'</a>)</p><p></p><p class="headingAnchor" id="H765499774"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Imaging may be used to identify potential sites for biopsy and to evaluate organ involvement. The nature of the clinical presentation determines the need for imaging (see <a class="local">'Clinical presentation'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphadenopathy</strong> – For the patient who does not have accessible peripheral lymphadenopathy, ultrasonography, computed tomography (CT), or positron emission tomography (PET) may identify a suspicious site and/or guide a tissue biopsy. (See  <a class="medical medical_review" href="/z/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mediastinal mass </strong>– For patients with a mediastinal mass, but without other accessible lymphadenopathy, chest CT and/or PET may identify a site for biopsy. Tissue biopsy may be obtained by CT-guided percutaneous approach, endobronchial biopsy, or a surgical procedure, such as anterior mediastinotomy (Chamberlain procedure), cervical mediastinoscopy, or video-assisted thoracoscopy/biopsy (VATS), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6967.html" rel="external">"Approach to the adult patient with a mediastinal mass", section on 'Tissue diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extranodal sites</strong> – For patients without identifiable adenopathy who are suspected of organ involvement, imaging may be useful for guiding a tissue biopsy. (See <a class="local">'Less common presentations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organ involvement</strong> – Imaging for evaluation of organ involvement is described below. (See <a class="local">'Evaluation of extranodal sites'</a> below.)</p><p></p><p>PET/CT is used for staging cHL, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma", section on 'PET/CT'</a>.)</p><p class="headingAnchor" id="H1273671310"><span class="h2">Tissue biopsy</span><span class="headingEndMark"> — </span>A tissue biopsy is required to diagnose cHL and to determine the histologic subtype. The site and type of biopsy is informed by the clinical presentation. </p><p>Excisional or incisional biopsy of a peripheral lymph node is generally preferred as the source of tissue because of ease of access, safety, and high yield and because it provides abundant material for microscopic evaluation, specialized testing, and histologic subtyping. Multiple core needle biopsies of a peripheral lymph node or via image-guided biopsy may be adequate in many cases, but fine needle aspiration (FNA) generally does <strong>not</strong> provide sufficient tissue for all required analyses and does not permit definitive histologic classification.</p><p>Selection of a lymph node for biopsy depends on the patient's clinical presentation. If multiple lymph node groups are enlarged, biopsy of suspicious cervical, supraclavicular, or axillary lymph nodes is generally favored; in contrast, inguinal lymph nodes are frequently distorted by prior inflammatory/immune reactions, and these changes may make the diagnosis of cHL more difficult. When the diagnosis of cHL is made from biopsy of an extranodal site, confirmation with a lymph node biopsy is desirable unless the diagnosis is considered unequivocal. (See <a class="local">'Diagnosis'</a> below.)</p><p>Pathologic evaluation of biopsy material is described below. (See <a class="local">'Pathology'</a> below.)</p><p class="headingAnchor" id="H2788994495"><span class="h2">Evaluation of extranodal sites</span><span class="headingEndMark"> — </span>Additional studies may be required for evaluation of patients who are suspected of having organ involvement based on history, physical examination, or laboratory studies. Following are examples of extranodal disease/organ involvement and methods for evaluation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver</strong> – Suspected liver involvement (eg, due to abdominal fullness/pain, nausea, jaundice, weight loss, abnormal liver function tests [LFTs]) should be evaluated with imaging. LFTs are not reliable in this setting, since they may be abnormal even in the absence of histologic involvement. </p><p></p><p class="bulletIndent1">Radiologic diagnosis of liver involvement by cHL is challenging because it usually consists of microscopic or small macroscopic foci. Some experts suggest that liver involvement should be documented with two different imaging techniques (eg, ultrasound, CT, MRI, PET) [<a href="#rid7">7,45</a>]. </p><p></p><p class="bulletIndent1">Ultrasound, CT, PET, and/or MRI may be used to guide a liver biopsy if no suspicious lymph node sites are identified. (See <a class="local">'Imaging'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spleen</strong> – PET/CT or MRI are the most reliable imaging approaches for evaluating suspected splenic involvement (eg, in patients with early satiety, weight loss, abdominal fullness, splenomegaly, or related findings). Spleen involvement is generally manifest as diffuse infiltration with miliary lesions, focal nodular lesions, and/or a large solitary mass; some patients with early stage disease have low level splenic uptake due to inflammation [<a href="#rid7">7,45</a>]. </p><p></p><p class="bulletIndent1">For patients with no other apparent sites for tissue biopsy, the evaluation of isolated splenomegaly is described separately. (See  <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Evaluation (splenomegaly)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system (CNS)</strong> – For patients with neurologic symptoms or signs, the CNS should be evaluated by lumbar puncture and MRI, with and without gadolinium. Although CNS involvement by cHL is extremely rare, it may be missed on PET/CT due to the increased physiologic FDG uptake in the normal brain. CNS involvement can be due to parenchymal and/or leptomeningeal involvement. </p><p></p><p class="bulletIndent1">Neurologic abnormalities may also be caused by a paraneoplastic neurologic syndrome. (See <a class="local">'Less common presentations'</a> above and  <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal (GI) tract</strong> – The gastrointestinal (GI) tract is rarely involved by cHL. CT with intravenous contrast may be required to distinguish GI tract involvement from that of adjacent abdominal lymphadenopathy. If indicated, endoscopy and biopsy are the preferred method to confirm suspected involvement. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone</strong> – For patients with focal bony pain, plain radiographs may reveal predominantly osteoblastic/sclerotic lesions. PET is highly sensitive for the identification of bony involvement. The approach to bone biopsy, if needed, is described separately. (See  <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">"Bone tumors: Diagnosis and biopsy techniques"</a>.)</p><p></p><p>Documentation of extranodal involvement by cHL is an important component of disease staging, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma", section on 'Extranodal involvement'</a>.)</p><p class="headingAnchor" id="H909573581"><span class="h2">Abnormal findings from FNA</span><span class="headingEndMark"> — </span>Some patients have already undergone fine needle aspiration (FNA) at the time of evaluation for cHL. </p><p>For the patient with FNA findings that are suspicious for cHL (eg, presence of Hodgkin/Reed-Sternberg cells and/or an unexplained polymorphous inflammatory cell infiltrate), we suggest a tissue biopsy to confirm the diagnosis and to determine the histologic subtype. Our reasons for suggesting a tissue biopsy rather than an FNA alone are described above. (See <a class="local">'Tissue biopsy'</a> above.)</p><p class="headingAnchor" id="H1117879135"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H517674158"><span class="h2">Microscopy</span><span class="headingEndMark"> — </span>In cHL, the lymph node is effaced by variable numbers of Hodgkin/Reed-Sternberg (HRS) cells admixed with a polymorphous inflammatory infiltrate. In general, HRS cells constitute only a small component of the involved tissue (eg, 0.1 to 10 percent) [<a href="#rid10">10</a>]. Characteristics of HRS cells are described below. (See <a class="local">'Hodgkin/Reed-Sternberg cells'</a> below.)</p><p>The composition of the inflammatory infiltrate varies according to the histologic subtype. The infiltrate generally includes variable percentages of small lymphocytes, eosinophils, neutrophils, macrophages (also referred to as histiocytes), plasma cells, and fibroblasts and may be associated with collagen deposition and fibrosis  (<a class="graphic graphic_picture graphicRef69090" href="/z/d/graphic/69090.html" rel="external">picture 1</a>). Granuloma formation is found in lymph nodes, spleen, or liver in approximately 15 percent of cHL cases, and they may or may not be associated with direct involvement by cHL. (See <a class="local">'Histologic subtypes'</a> below.)</p><p>Grading schemes have been developed within specific subtypes of cHL (eg, nodular sclerosis cHL), but they have not been proven to be useful in determining prognosis and are not used for selecting treatment. Grading schemes and other features of the cellular infiltrate that may have prognostic significance for cHL are described separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma", section on 'Other prognostic factors'</a>.)</p><p class="headingAnchor" id="H3365933072"><span class="h2">Hodgkin/Reed-Sternberg cells</span></p><p class="headingAnchor" id="H1061595746"><span class="h3">Morphology</span><span class="headingEndMark"> — </span>Hodgkin/Reed-Sternberg (HRS) cell is a collective term for classic Reed-Sternberg (RS) cells and characteristic variant cells that are referred to as Hodgkin cells. </p><p>Prototypical RS cells have at least two nucleoli in separate nuclear lobes and present a characteristic "owl's eyes" appearance  (<a class="graphic graphic_picture graphicRef69090" href="/z/d/graphic/69090.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef79314" href="/z/d/graphic/79314.html" rel="external">picture 2</a>). RS cells of cHL have rounded bilobed, double, or multiple nuclei; pale chromatin; a prominent eosinophilic nucleolus with perinucleolar clearing (halo); and abundant, slightly basophilic cytoplasm [<a href="#rid10">10</a>]. </p><p>Characteristic RS variant cells include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hodgkin cell</strong> – Mononuclear variants of RS cells  (<a class="graphic graphic_picture graphicRef121338" href="/z/d/graphic/121338.html" rel="external">picture 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lacunar cells</strong> – Lacunar cells have multilobated nuclei, small nucleoli, and abundant, and pale cytoplasm in what appears to be an empty space (a lacune)  (<a class="graphic graphic_picture graphicRef66711" href="/z/d/graphic/66711.html" rel="external">picture 4</a>). The lacune results from shredding or partial loss of cellular content upon sectioning when tissue fixation is incomplete. Lacunar cells are characteristically seen only in tissues fixed with formalin, which is not as effective at penetrating and fixing tissues as other fixatives used by hematopathologists (eg, B+ fixative).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mummified cells</strong> – Mummified cells are neoplastic cells that contain condensed cytoplasm and pyknotic reddish nuclei with smudged chromatin  (<a class="graphic graphic_picture graphicRef66711" href="/z/d/graphic/66711.html" rel="external">picture 4</a>).</p><p></p><p>Lymphocytic and histiocytic (L&amp;H) cells are a variant of RS cells that are seen in nodular lymphocyte predominant HL, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging", section on 'LP cells'</a>.)</p><p class="headingAnchor" id="H1969933220"><span class="h3">Immunophenotype</span><span class="headingEndMark"> — </span>The immunophenotype of HRS cells is typically characterized by: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>CD30 and CD15</strong> – CD30 is expressed by virtually 100 percent of HL cases, while CD15 is expressed in 75 to 85 percent  (<a class="graphic graphic_picture graphicRef73875 graphicRef54023" href="/z/d/graphic/73875.html" rel="external">picture 5A-B</a>) [<a href="#rid10">10</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CD45</strong> – HRS cells do <strong>not</strong> express CD45 (leukocyte common antigen), which distinguishes them from normal leukocytes and most (but not all) other types of malignant lymphoma cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>B cell antigens </strong>– Expression of the B cell-specific surface antigens, CD20, CD79a, and/or CD19, is characteristically either absent or is seen on only a subset of HRS cells [<a href="#rid46">46,47</a>]. PAX5/BSAP (a key B cell transcription factor) is weakly expressed in approximately 95 percent of cases, whereas expression of other B cell-specific transcription factors (BOB1, OCT2) is typically diminished or lost altogether in HRS cells [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T cell antigens</strong> – Pan-T cell antigens (eg, CD3, CD7) are not expressed by HRS cells, but expression of a single T cell antigen (eg, CD4) may occasionally be seen; expression of multiple T cell antigens by HRS cells is rare [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PD-1 and its ligands</strong> – HRS cells express PD-L1 and PD-L2, which are ligands for the PD-1 immune checkpoint receptor. Other antigens expressed by HRS cells that are involved with immune cell interactions include CD83, CD40, and CD86 [<a href="#rid46">46,47,50-55</a>].</p><p></p><p class="bulletIndent1">The role of the PD-1 checkpoint in immune evasion by HRS cells is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma", section on 'Immune evasion'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus (EBV) antigens</strong> – In EBV-positive cases of cHL, the tumor cells express EBV latent membrane protein (LMP)-1 and LMP-2, but not Epstein-Barr nuclear antigen (EBNA)-2. The presence of EBV in various histologic subtypes and roles of EBV gene products in HL pathogenesis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors", section on 'Epstein-Barr virus'</a> and  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antigens</strong> that may be expressed by HRS cell include CD25, HLA-DR, ICAM-1, Fascin, CD95 (apo-1/fas), and TRAF1. </p><p></p><p>Multiparameter flow cytometry utilizing ≥6 colors can identify rare RS cells in a tissue specimen, but is not sufficient to establish the diagnosis or characterize the histologic subtype of cHL, as described below. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H4164717183"><span class="h3">Cytogenetics</span><span class="headingEndMark"> — </span>Clonal cytogenetic abnormalities are found in most cases, but no consistent or specific karyotypic finding has been associated with cHL [<a href="#rid56">56-58</a>]. </p><p>Chromosomal instability is manifest by diverse cytogenetic abnormalities and intraclonal variability of HRS cells. Clonal chromosomal abnormalities were reported in all cases of cHL that were tested by fluorescence in situ hybridization (FISH) [<a href="#rid59">59,60</a>]. Aneuploidy and hypertetraploidy are consistent with the multi-nucleation of RS cells. (See <a class="local">'Morphology'</a> above.)</p><p>There is frequent amplification of chromosome 9p24.1, which is associated with copy number gains of <em>PDL1</em> (also known as CD274 or B7 homolog 1),<em> PDL2</em>, and <em>JAK2</em>, all of which contribute to the pathogenesis of HL [<a href="#rid61">61,62</a>]. Although many cases of cHL show abnormalities of chromosome 14q, it is rare to identify the t(14;18<em>)/BCL2</em> rearrangement that is typical for B cell non-Hodgkin lymphomas. (See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma", section on 'Cytogenetics and mutations'</a>.)</p><p class="headingAnchor" id="H4126631484"><span class="h3">Molecular features</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunoglobulin (</strong><strong><em>Ig</em></strong><strong>) and T cell receptor (</strong><strong><em>TCR</em></strong><strong>) gene rearrangements</strong> – Clonal immunoglobulin (<em>Ig</em>) gene rearrangements can be detected in &gt;98 percent of cHL by polymerase chain reaction (PCR) on microdissected single HRS cells [<a href="#rid10">10</a>]. The presence of mutated <em>VDJ</em> rearrangements indicates that HRS cells originated from germinal center or post-germinal center B cells. (See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma"</a>.)</p><p></p><p class="bulletIndent1">Even in the rare cases of cHL with T cell antigen expression, most have clonal <em>Ig</em> gene rearrangements; only one-third has <em>TCR</em> gene rearrangements [<a href="#rid63">63</a>]. cHL of T cell origin, if it occurs at all, is extremely rare.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutations </strong>– The mutational landscape of cHL is heterogeneous, but most cases of cHL have abnormalities of intracellular signaling (eg, NF-kB or JAK-STAT pathways) and/or immune evasion (eg, PD-1 related genes).</p><p></p><p class="bulletIndent1">The most common mutations in HRS cells involve beta-2 microglobulin (B2M; approximately 70 percent of cases). Inactivating mutations of <em>B2M</em> lead to loss of expression of major histocompatibility complex (MHC) class I and contribute to immune evasion by HRS cells [<a href="#rid64">64</a>]. Whole exome sequencing of HRS cells from 34 patients with cHL detected mutations of <em>STAT6</em> and <em>SOCS1</em> in 32 and 59 percent of cases, respectively [<a href="#rid65">65</a>]. Abnormalities of the JAK-STAT pathway were reported in nearly 90 percent of cases, including mutations of transducers (eg, <em>JAK1, JAK2, STAT3, STAT5B</em>) and inhibitors (eg, <em>PTPN1</em>). Other mutations include genes that encode components of the NF-kB, PI3K/AKT, Notch, and immune checkpoint pathways [<a href="#rid66">66</a>]. As an example, inactivating mutations in <em>TNFAIP3</em>, which encodes a negative regulator of NF-kB signaling and is predicted to upregulate NF-kB signaling, were reported in 44 percent of cHL [<a href="#rid67">67</a>]. Mutations of other components of the NF-kB signaling pathway (eg, <em>TRAF3 </em>and<em> MAP3K14</em>) have also been reported [<a href="#rid68">68</a>]. Mutations of <em>GMCSF/IL3</em> and <em>CBP/EP300</em> and variants of <em>BTK</em>, <em>CARD11</em>, and <em>BCL10</em> may affect HRS cell viability [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1">Copy number gains of <em>REL</em>, <em>BCL11A</em>, <em>XPO1</em>, and <em>MYCN</em> (chromosome 2) and loss of <em>TNFAIP3</em> (chromosome 6), <em>ATM</em> and <em>BIRC3</em> (chromosome 11), and <em>RB1</em> and <em>BRCA2</em> (chromosome 13) are common in cHL. In one study, 97 percent of 108 cHL cases had concordant gains of the <em>PDL1</em> and <em>PDL2</em> loci (polysomy, 5 percent; copy gain, 56 percent; amplification, 36 percent) [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1">Roles of the various mutated genes and signaling pathways in the pathogenesis of cHL are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene expression </strong>– Despite their derivation from germinal center B lymphocytes, HRS cells express genes aberrantly and have lost much of the B cell-specific expression program [<a href="#rid70">70-77</a>]. HRS cells have a gene expression profile that is distinct from other types of lymphoma. Based on patterns of gene expression, there appears to be at least two classes of cHL; their gene expression signatures resemble those associated with activity of the transcription factors, NOTCH1, MYC, and IRF4. </p><p></p><p class="bulletIndent1">Altered expression of NF-kB B target genes, components of the JAK/STAT signaling pathway, and/or the AP-1 complex is characteristic of cHL [<a href="#rid71">71,78-82</a>]. Interestingly, EBV+ and EBV- cases of cHL have similar expression profiles, which is consistent with the idea that EBV components mimic the effects of somatic mutations found in EBV-cHL. (See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma", section on 'Epstein-Barr virus'</a>.)</p><p></p><p class="headingAnchor" id="H2607228382"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of cHL should be suspected in a patient with lymphadenopathy or a mediastinal mass on a chest radiograph, with or without B symptoms (ie, fever, sweats, weight loss). However, the clinical presentation of cHL is variable and a patient may present with nonspecific symptoms, such as fatigue, pruritus, or other less common or atypical clinical findings, as described above. (See <a class="local">'Clinical presentation'</a> above.)</p><p>The diagnosis of cHL requires the following microscopic findings plus the defining immunophenotype of Hodgkin/Reed-Sternberg (HRS) cells:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymph node</strong> – Diagnostic HRS cells in a polymorphous inflammatory infiltrate of small lymphocytes, eosinophils, neutrophils, histiocytes, plasma cells, and fibroblasts, with or without collagen deposition and fibrosis. The HRS cells may be prototypical Reed-Sternberg (RS) cells or Hodgkin variants, as described above. (See <a class="local">'Morphology'</a> above.)</p><p></p><p class="bulletIndent1">Diagnosis of cHL involvement of a secondary site (eg, bone marrow, liver) requires the presence of CD30+ mononuclear cells in an appropriate inflammatory background; diagnostic RS cells are not required to make a diagnosis of cHL at an extranodal site in a patient with known disease [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotype</strong> – HRS cells of cHL express CD30, but not CD45 or CD3  (<a class="graphic graphic_table graphicRef57079" href="/z/d/graphic/57079.html" rel="external">table 3</a>). Most cases of cHL express CD15, but the absence of CD15 does not preclude a diagnosis of HL. However, absence of both CD15 and CD30 strongly points to other diagnoses. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p>Determination of the histologic subtype is an essential aspect of the diagnosis of cHL. (See <a class="local">'Histologic subtypes'</a> below.)</p><p>Pretreatment evaluation, staging, and treatment stratification are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H2597428284"><span class="h1">HISTOLOGIC SUBTYPES</span></p><p class="headingAnchor" id="H58291302"><span class="h2">Nodular sclerosis</span><span class="headingEndMark"> — </span>Nodular sclerosis cHL (NSCHL) is characterized by a nodular growth pattern in the lymph node, with fibrous bands separating cellular nodules  (<a class="graphic graphic_picture graphicRef59583" href="/z/d/graphic/59583.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef54520" href="/z/d/graphic/54520.html" rel="external">picture 7</a>). Diagnostic RS cells may be rare; typically, the majority of HRS cells in NSCHL are lacunar cells. The inflammatory background usually contains eosinophils, macrophages, and neutrophils and may have areas of necrosis.</p><p>Some histologic variants of NSCHL have been described:</p><p class="bulletIndent1"><span class="glyph">●</span>In some cases, the fibrous bands may be poorly developed or inconspicuous, making the distinction from other forms of cHL difficult. This appearance has been referred to as the "cellular phase" of NSCHL [<a href="#rid83">83,84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Syncytial NSCHL refers to tumors in which lacunar cells are found in large aggregates or sheets, which may lead to a focal loss of the nodular sclerotic pattern  (<a class="graphic graphic_picture graphicRef82231" href="/z/d/graphic/82231.html" rel="external">picture 8</a>) [<a href="#rid85">85</a>]. </p><p></p><p class="headingAnchor" id="H1450506060"><span class="h2">Mixed cellularity</span><span class="headingEndMark"> — </span>Mixed cellularity cHL (MCCHL) is a heterogeneous subtype of classic HL with a diffuse or vaguely nodular growth pattern without band-forming sclerosis  (<a class="graphic graphic_picture graphicRef72292" href="/z/d/graphic/72292.html" rel="external">picture 9</a>). Fine interstitial fibrosis may be present, and classic diagnostic RS cells are readily identified. The background infiltrate is variable, but typically consists of eosinophils, neutrophils, macrophages, and plasma cells  (<a class="graphic graphic_picture graphicRef62690" href="/z/d/graphic/62690.html" rel="external">picture 10</a>) [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H2391221509"><span class="h2">Lymphocyte rich</span><span class="headingEndMark"> — </span>Lymphocyte-rich cHL (LRCHL) most commonly has a nodular growth pattern, but may also be diffuse. The background infiltrate consists predominantly of lymphocytes, with few eosinophils or neutrophils  (<a class="graphic graphic_picture graphicRef82910" href="/z/d/graphic/82910.html" rel="external">picture 11</a>). Diagnostic RS cells and mononuclear Hodgkin cells are present. Some cases of LRCHL have a nodular pattern, containing remnants of regressed germinal centers, with both classic and variant RS cells in the mantle zones and interfollicular regions; this entity has been termed "follicular" HL, or nodular lymphocyte-rich cHL [<a href="#rid86">86,87</a>]. </p><p>In some cases, HRS cells of LRCHL resemble the lymphocytic and histiocytic (L&amp;H) cells that are characteristic of nodular lymphocyte-rich HL. (See  <a class="medical medical_review" href="/z/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging", section on 'Pathology'</a>.)</p><p class="headingAnchor" id="H3083852959"><span class="h2">Lymphocyte depleted</span><span class="headingEndMark"> — </span>Lymphocyte-depleted cHL (LDCHL) is the least common subtype of cHL, accounting for &lt;1 percent of cases. LDCHL has a diffuse growth pattern and often appears hypocellular due to fibrosis, necrosis, and a paucity of inflammatory cells  (<a class="graphic graphic_picture graphicRef53036" href="/z/d/graphic/53036.html" rel="external">picture 12</a>). Typically, large numbers of diagnostic RS cells and bizarre variant HRS cells are present  (<a class="graphic graphic_picture graphicRef62690" href="/z/d/graphic/62690.html" rel="external">picture 10</a>). Compared with other cHL subtypes, patients with LDCHL are more likely to present with advanced stage disease (74 versus 42 percent) and systemic B symptoms (76 versus 41 percent) [<a href="#rid88">88</a>].</p><p>The terms "reticular" variant or "Hodgkin sarcoma" have been used to describe LDCHL with confluent sheets of HRS cells  (<a class="graphic graphic_picture graphicRef52406" href="/z/d/graphic/52406.html" rel="external">picture 13</a>) [<a href="#rid83">83,89</a>]; this variant may be particularly difficult to distinguish from anaplastic large cell lymphoma [<a href="#rid90">90,91</a>]. (See <a class="local">'Anaplastic large cell lymphoma'</a> below.)</p><p class="headingAnchor" id="H3189011158"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Numerous conditions cause lymphadenopathy that may be accompanied by fever, sweats, weight loss, or other findings. The differential diagnosis includes infectious, autoimmune, and various malignant disorders. </p><p class="headingAnchor" id="H3742269734"><span class="h2">Reactive processes</span><span class="headingEndMark"> — </span>Infectious, autoimmune, and other inflammatory processes can cause lymphadenopathy, organomegaly, fever, and other systemic symptoms that can be difficult to distinguish from cHL. Reactive processes have a polymorphous infiltrate that resembles cHL, but they lack diagnostic Hodgkin/Reed-Sternberg cells (HRS; which are defined by their distinctive morphology and immunophenotype). (See <a class="local">'Hodgkin/Reed-Sternberg cells'</a> above.) </p><p>Differentiating between reactive processes and cHL is especially challenging if a fine needle aspirate (FNA) was performed, because it yields only limited cellular material and does not provide intact nodal architecture. As described above, an excisional biopsy or multiple core biopsies is required to confirm the diagnosis of cHL and distinguish it from reactive causes of lymphadenopathy. (See <a class="local">'Tissue biopsy'</a> above.) </p><p>Evaluation and diagnosis of various conditions that may cause lymphadenopathy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults"</a>.)</p><p class="headingAnchor" id="H491449308"><span class="h2">EBV-positive mucocutaneous ulcer</span><span class="headingEndMark"> — </span>Epstein-Barr virus (EBV)-positive mucocutaneous ulcer is a disorder characterized by isolated circumscribed ulcerative lesions, typically in older individuals and sometimes in the setting of immunosuppression [<a href="#rid10">10,92</a>]. The lesions are most common in the oropharynx, but may also occur in the skin or gastrointestinal tract. The lesions contain a polymorphous inflammatory infiltrate mixed with scattered EBV-infected B cells, which may include cells that morphologically and immunophenotypically resemble HRS cells. This entity is distinguished from cHL by its extranodal presentation, benign course, frequent spontaneous regression, and excellent response to conservative treatment [<a href="#rid92">92,93</a>]. (See  <a class="medical medical_review" href="/z/d/html/109157.html" rel="external">"Classification of primary cutaneous lymphomas", section on 'EBV-positive mucocutaneous ulcer'</a>.)</p><p class="headingAnchor" id="H3313498204"><span class="h2">Nodular lymphocyte-predominant HL</span><span class="headingEndMark"> — </span>Nodular lymphocyte-predominant HL (NLPHL) can resemble cHL with regard to clinical and pathologic presentation, and can be especially challenging to distinguish from lymphocyte-rich cHL (LRCHL). NLPHL can generally be distinguished from cHL by the presence of lymphocytic and histiocytic (L&amp;H) HRS cells embedded within nodules composed mainly reactive B cells  (<a class="graphic graphic_picture graphicRef82911" href="/z/d/graphic/82911.html" rel="external">picture 14</a>), and distinctive immunophenotypic and molecular features  (<a class="graphic graphic_table graphicRef57079" href="/z/d/graphic/57079.html" rel="external">table 3</a>), including the uniform expression of B cell antigens (eg, CD20) and the absence of CD30 and CD15. NLPHL is rarely, if ever, Epstein-Barr virus (EBV)-positive, which may also help to distinguish it from cHL. (See  <a class="medical medical_review" href="/z/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging"</a>.)</p><p class="headingAnchor" id="H868339507"><span class="h2">Anaplastic large cell lymphoma</span><span class="headingEndMark"> — </span>Anaplastic large cell lymphoma (ALCL) may be difficult to distinguish from certain variants of lymphocyte-depleted cHL (LDCHL) and, in some cases, can produce inflammatory responses and tissue fibrosis that mimic the host response to HRS cells [<a href="#rid90">90,91,94</a>]. However, cases can generally be resolved by a combination of morphologic and immunophenotypic features as either:</p><p class="bulletIndent1"><span class="glyph">●</span>Classic Hodgkin lymphoma: CD15+, CD30+, PAX/BSAP+, T cell antigens-, ALK-</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anaplastic large cell lymphoma: CD15-, strongly CD30+, PAX5/BSAP-, positive for one or more T cell antigens, ALK+/-, and positive for cytotoxic markers (perforin, granzyme B, TIA-1)</p><p></p><p>Nonetheless, there are occasional cases in which the combination of morphology, immunophenotype, and even genetic studies may not resolve ALCL and HL with certainty. (See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"</a>.)</p><p class="headingAnchor" id="H2569832483"><span class="h2">Other B cell lymphomas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary mediastinal B cell lymphoma (PMBL)</strong> – Primary mediastinal B cell lymphoma (PMBL) and nodular sclerosis cHL (NSCHL) share certain clinical features, including the presence of a mediastinal mass and occurrence predominantly in young women. Biopsy of PMBL may reveal cells that resemble HRS cells of cHL and the entities have similar patterns of gene expression. However, in PMBL, the malignant cells typically express pan-B cell antigens, have weak expression of CD30, and only rarely express CD15. In contrast, HRS cells of cHL typically express both CD15 and CD30. Expression of fascin by HRS cells can help to distinguish EBV-negative cHL from PMBL [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/z/d/html/4713.html" rel="external">"Primary mediastinal large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mediastinal gray zone lymphoma</strong> – Mediastinal gray zone lymphoma (MGZL) is a term that is commonly applied to lymphomas that combine features of PMBL and cHL and thereby fall into a "gray-zone." In the World Health Organization classification, these are formally described as B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma [<a href="#rid10">10</a>]. MGZL is most common in young men who present with a large anterior mediastinal mass [<a href="#rid96">96,97</a>]. Tumors are histologically heterogeneous with strong expression of CD15 and CD30 by the malignant cells [<a href="#rid10">10</a>]. Recognition of MZGL is clinically relevant, because compared with cHL and PMBL, MGZL generally has a more aggressive course and inferior outcomes [<a href="#rid98">98</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T cell histiocyte-rich large B cell lymphoma (THRLBCL)</strong> – T cell histiocyte-rich large B cell lymphoma (THRLBCL) can also be difficult to distinguish from cHL. THRLBCL occurs most commonly in middle-aged males and, like cHL, the tumor cells may comprise only a minor fraction of the total cellularity. However, the malignant B cells in THRLBCL usually have an immunophenotype similar to other B cell lymphomas (eg, positive for pan-B cell markers and negative for CD15, CD30, and EBV). (See  <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'T cell histiocyte-rich large B cell lymphoma'</a>.)</p><p></p><p class="headingAnchor" id="H158285898"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120313.html" rel="external">"Society guideline links: Management of Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H989410"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15858.html" rel="external">"Patient education: Hodgkin lymphoma in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/683.html" rel="external">"Patient education: Hodgkin lymphoma in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic Hodgkin lymphoma (cHL)</strong> – cHL refers to lymphoid neoplasms in which malignant Hodgkin/Reed-Sternberg (HRS) cells are admixed with a heterogeneous population of non-neoplastic inflammatory cells. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Most patients present with asymptomatic lymphadenopathy or a mass on chest radiograph; these findings may be accompanied by B symptoms (fever, night sweats, weight loss), pruritus, or other symptoms. cHL generally proceeds from a lymph node to adjacent lymph nodes before disseminating to nonadjacent sites and organs  (<a class="graphic graphic_figure graphicRef55422" href="/z/d/graphic/55422.html" rel="external">figure 1</a>). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical</strong> – History of lymphadenopathy, B symptoms, pruritus, alcohol-induced pain, or other symptoms. Examination should document the size, number, and involved regions of lymph nodes and hepatosplenomegaly. (See <a class="local">'Typical presentations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – (See <a class="local">'Laboratory studies'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Complete blood count (CBC)</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Erythrocyte sedimentation rate (ESR)</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Serum chemistries:</strong> Electrolytes, liver and renal function tests, albumin, and lactate dehydrogenase (LDH)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging</strong> – Positron emission tomography (PET)/computed tomography (CT); other imaging as clinically indicated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biopsy</strong> – An excisional biopsy (or multiple core needle biopsies) is required to diagnose cHL and determine the histologic subtype; a fine needle aspiration (FNA) is generally <strong>not</strong> sufficient for diagnosis and classification of cHL. (See <a class="local">'Tissue biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – cHL should be suspected in a patient with lymphadenopathy, a chest mass, unexplained B symptoms, or alcohol-associated pain. </p><p></p><p class="bulletIndent1">The diagnosis requires characteristic microscopic findings of Hodgkin/Reed-Sternberg (HRS) cells  (<a class="graphic graphic_picture graphicRef69090" href="/z/d/graphic/69090.html" rel="external">picture 1</a>) (or variant forms) that express CD30, but do not express CD45 or CD3  (<a class="graphic graphic_table graphicRef57079" href="/z/d/graphic/57079.html" rel="external">table 3</a>), admixed with a pleomorphic inflammatory cell infiltrate. (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic subtypes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nodular sclerosis cHL </strong> (<a class="graphic graphic_picture graphicRef59583" href="/z/d/graphic/59583.html" rel="external">picture 6</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mixed cellularity cHL </strong> (<a class="graphic graphic_picture graphicRef72292" href="/z/d/graphic/72292.html" rel="external">picture 9</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphocyte rich cHL</strong>  (<a class="graphic graphic_picture graphicRef82910" href="/z/d/graphic/82910.html" rel="external">picture 11</a>)<strong> </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphocyte depleted cHL </strong> (<a class="graphic graphic_picture graphicRef53036" href="/z/d/graphic/53036.html" rel="external">picture 12</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Other causes of lymphadenopathy, including infectious, autoimmune, benign, and other malignancies, should be excluded by clinical and pathologic evaluation. cHL must also be distinguished from lymphocyte-predominant HL, anaplastic lymphoma, and various other non-Hodgkin lymphomas. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1410430700"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate acknowledges the late Peter M Mauch, MD, who contributed to earlier versions of this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol 2005; 23:5739.</a></li><li><a class="nounderline abstract_t">Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 1993; 71:2062.</a></li><li class="breakAll">Kaplan HS. Hodgkin's Disease, 2nd ed, Harvard University Press, Cambridge, MA 1980.</li><li><a class="nounderline abstract_t">Peters MV, Alison RE, Bush RS. Natural history of Hodgkin's disease as related to staging. Cancer 1966; 19:308.</a></li><li><a class="nounderline abstract_t">KAPLAN HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 1962; 78:553.</a></li><li><a class="nounderline abstract_t">Rosenberg SA, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin's disease. Cancer Res 1966; 26:1225.</a></li><li><a class="nounderline abstract_t">Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059.</a></li><li><a class="nounderline abstract_t">Good GR, DiNubile MJ. Images in clinical medicine. Cyclic fever in Hodgkin's disease (Pel-Ebstein fever). N Engl J Med 1995; 332:436.</a></li><li><a class="nounderline abstract_t">Gobbi PG, Cavalli C, Gendarini A, et al. Reevaluation of prognostic significance of symptoms in Hodgkin's disease. Cancer 1985; 56:2874.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Bobrove AM. Alcohol-related pain and Hodgkin's disease. West J Med 1983; 138:874.</a></li><li><a class="nounderline abstract_t">Kaplan HS, Dorfman RF, Nelsen TS, Rosenberg SA. Staging laparotomy and splenectomy in Hodgkin's disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients. Natl Cancer Inst Monogr 1973; 36:291.</a></li><li><a class="nounderline abstract_t">Cervantes F, Briones J, Bruguera M, et al. Hodgkin's disease presenting as a cholestatic febrile illness: incidence and main characteristics in a series of 421 patients. Ann Hematol 1996; 72:357.</a></li><li><a class="nounderline abstract_t">Dourakis SP, Tzemanakis E, Deutsch M, et al. Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Eur J Gastroenterol Hepatol 1999; 11:1055.</a></li><li><a class="nounderline abstract_t">Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol 1995; 133:322.</a></li><li><a class="nounderline abstract_t">Perifanis V, Sfikas G, Tziomalos K, et al. Skin involvement in Hodgkin's disease. Cancer Invest 2006; 24:401.</a></li><li><a class="nounderline abstract_t">Macintyre EA, Vaughan Hudson B, Linch DC, et al. The value of staging bone marrow trephine biopsy in Hodgkin's disease. Eur J Haematol 1987; 39:66.</a></li><li><a class="nounderline abstract_t">Howell SJ, Grey M, Chang J, et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol 2002; 119:408.</a></li><li><a class="nounderline abstract_t">Vassilakopoulos TP, Angelopoulou MK, Constantinou N, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood 2005; 105:1875.</a></li><li><a class="nounderline abstract_t">El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012; 30:4508.</a></li><li><a class="nounderline abstract_t">Adams HJ, Kwee TC, de Keizer B, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol 2014; 25:921.</a></li><li><a class="nounderline abstract_t">Re D, Fuchs M, Schober T, et al. CNS involvement in Hodgkin's lymphoma. J Clin Oncol 2007; 25:3182.</a></li><li><a class="nounderline abstract_t">Morawa E, Ragam A, Sirota R, Nabhan C. Hodgkin's lymphoma involving the CNS. J Clin Oncol 2007; 25:1437.</a></li><li><a class="nounderline abstract_t">de Castro AF, Júnior AS, de Lins e Horta H, et al. Primary intracerebral Hodgkin lymphoma. Br J Haematol 2007; 138:562.</a></li><li><a class="nounderline abstract_t">Gerstner ER, Abrey LE, Schiff D, et al. CNS Hodgkin lymphoma. Blood 2008; 112:1658.</a></li><li><a class="nounderline abstract_t">Graus F, Dalmau J, Valldeoriola F, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74:55.</a></li><li><a class="nounderline abstract_t">Graus F, Gultekin SH, Ferrer I, et al. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol 1998; 96:1.</a></li><li><a class="nounderline abstract_t">Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 1992; 42:1938.</a></li><li><a class="nounderline abstract_t">Batchelor TT, Platten M, Palmer-Toy DE, et al. Chorea as a paraneoplastic complication of Hodgkin's disease. J Neurooncol 1998; 36:185.</a></li><li><a class="nounderline abstract_t">Caress JB, Abend WK, Preston DC, Logigian EL. A case of Hodgkin's lymphoma producing neuromyotonia. Neurology 1997; 49:258.</a></li><li><a class="nounderline abstract_t">Deodhare S, O'Connor P, Ghazarian D, Bilbao JM. Paraneoplastic limbic encephalitis in Hodgkin's disease. Can J Neurol Sci 1996; 23:138.</a></li><li><a class="nounderline abstract_t">Hughes RA, Britton T, Richards M. Effects of lymphoma on the peripheral nervous system. J R Soc Med 1994; 87:526.</a></li><li><a class="nounderline abstract_t">Plante-Bordeneuve V, Baudrimont M, Gorin NC, Gherardi RK. Subacute sensory neuropathy associated with Hodgkin's disease. J Neurol Sci 1994; 121:155.</a></li><li><a class="nounderline abstract_t">Ferrari P, Federico M, Grimaldi LM, Silingardi V. Stiff-man syndrome in a patient with Hodgkin's disease. An unusual paraneoplastic syndrome. Haematologica 1990; 75:570.</a></li><li><a class="nounderline abstract_t">Briani C, Vitaliani R, Grisold W, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011; 76:705.</a></li><li><a class="nounderline abstract_t">Graus F, Ariño H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 2014; 123:3230.</a></li><li><a class="nounderline abstract_t">Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med 1986; 80:63.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1983. A 24-year-old man with cervical lymphadenopathy and the nephrotic syndrome. N Engl J Med 1983; 308:888.</a></li><li><a class="nounderline abstract_t">Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82:1383.</a></li><li><a class="nounderline abstract_t">Rieke JW, Donaldson SS, Horning SJ. Hypercalcemia and vitamin D metabolism in Hodgkin's disease. Is there an underlying immunoregulatory relationship? Cancer 1989; 63:1700.</a></li><li><a class="nounderline abstract_t">Shah SJ, Warrier RP, Ode DL, et al. Immune thrombocytopenia and hemolytic anemia associated with Hodgkin disease. J Pediatr Hematol Oncol 1996; 18:227.</a></li><li><a class="nounderline abstract_t">Sierra RD. Coombs-positive hemolytic anemia in Hodgkin's disease: case presentation and review of the literature. Mil Med 1991; 156:691.</a></li><li><a class="nounderline abstract_t">Di Biagio E, Sánchez-Borges M, Desenne JJ, et al. Eosinophilia in Hodgkin's disease: a role for interleukin 5. Int Arch Allergy Immunol 1996; 110:244.</a></li><li><a class="nounderline abstract_t">Teruya-Feldstein J, Jaffe ES, Burd PR, et al. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999; 93:2463.</a></li><li><a class="nounderline abstract_t">Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32:3048.</a></li><li><a class="nounderline abstract_t">Zukerberg LR, Collins AB, Ferry JA, Harris NL. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol 1991; 139:475.</a></li><li><a class="nounderline abstract_t">Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol 1991; 139:701.</a></li><li><a class="nounderline abstract_t">Schmitz R, Stanelle J, Hansmann ML, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009; 4:151.</a></li><li><a class="nounderline abstract_t">Venkataraman G, Song JY, Tzankov A, et al. Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival. Blood 2013; 121:1795.</a></li><li><a class="nounderline abstract_t">Li Z, Ju X, Lee K, et al. CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica 2018; 103:655.</a></li><li><a class="nounderline abstract_t">Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85:780.</a></li><li><a class="nounderline abstract_t">Munro JM, Freedman AS, Aster JC, et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83:793.</a></li><li><a class="nounderline abstract_t">Diepstra A, van Imhoff GW, Karim-Kos HE, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007; 25:3101.</a></li><li><a class="nounderline abstract_t">Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184:1495.</a></li><li><a class="nounderline abstract_t">Pinkus GS, Pinkus JL, Langhoff E, et al. Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation? Am J Pathol 1997; 150:543.</a></li><li><a class="nounderline abstract_t">Poppema S, Kaleta J, Hepperle B. Chromosomal abnormalities in patients with Hodgkin's disease: evidence for frequent involvement of the 14q chromosomal region but infrequent bcl-2 gene rearrangement in Reed-Sternberg cells. J Natl Cancer Inst 1992; 84:1789.</a></li><li><a class="nounderline abstract_t">M'kacher R, Bennaceur-Griscelli A, Girinsky T, et al. Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers. Int J Radiat Oncol Biol Phys 2007; 68:465.</a></li><li><a class="nounderline abstract_t">Schlegelberger B, Weber-Matthiesen K, Himmler A, et al. Cytogenetic findings and results of combined immunophenotyping and karyotyping in Hodgkin's disease. Leukemia 1994; 8:72.</a></li><li><a class="nounderline abstract_t">Weber-Matthiesen K, Deerberg J, Poetsch M, et al. Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood 1995; 86:1464.</a></li><li><a class="nounderline abstract_t">Inghirami G, Macri L, Rosati S, et al. The Reed-Sternberg cells of Hodgkin disease are clonal. Proc Natl Acad Sci U S A 1994; 91:9842.</a></li><li><a class="nounderline abstract_t">Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116:3268.</a></li><li><a class="nounderline abstract_t">Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol 2016; 34:2690.</a></li><li><a class="nounderline abstract_t">Müschen M, Rajewsky K, Bräuninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 2000; 191:387.</a></li><li><a class="nounderline abstract_t">Reichel J, Chadburn A, Rubinstein PG, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015; 125:1061.</a></li><li><a class="nounderline abstract_t">Tiacci E, Ladewig E, Schiavoni G, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood 2018; 131:2454.</a></li><li><a class="nounderline abstract_t">Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018; 131:2413.</a></li><li><a class="nounderline abstract_t">Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206:981.</a></li><li><a class="nounderline abstract_t">Otto C, Giefing M, Massow A, et al. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br J Haematol 2012; 157:702.</a></li><li><a class="nounderline abstract_t">Mata E, Díaz-López A, Martín-Moreno AM, et al. Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. Oncotarget 2017; 8:111386.</a></li><li><a class="nounderline abstract_t">Tiacci E, Döring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012; 120:4609.</a></li><li><a class="nounderline abstract_t">Mathas S, Janz M, Hummel F, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2006; 7:207.</a></li><li><a class="nounderline abstract_t">Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001; 97:496.</a></li><li><a class="nounderline abstract_t">Ehlers A, Oker E, Bentink S, et al. Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype. Leukemia 2008; 22:835.</a></li><li><a class="nounderline abstract_t">Janz M, Hummel M, Truss M, et al. Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood 2006; 107:2536.</a></li><li><a class="nounderline abstract_t">Küppers R, Klein U, Schwering I, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 2003; 111:529.</a></li><li><a class="nounderline abstract_t">Marafioti T, Pozzobon M, Hansmann ML, et al. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004; 103:188.</a></li><li><a class="nounderline abstract_t">Schwering I, Bräuninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101:1505.</a></li><li><a class="nounderline abstract_t">Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196:605.</a></li><li><a class="nounderline abstract_t">Hinz M, Löser P, Mathas S, et al. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97:2798.</a></li><li><a class="nounderline abstract_t">Höpken UE, Foss HD, Meyer D, et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 2002; 99:1109.</a></li><li><a class="nounderline abstract_t">Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99:618.</a></li><li><a class="nounderline abstract_t">Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21:4104.</a></li><li><a class="nounderline abstract_t">Lukes R, Butler J, Hicks E. Natural history of Hodgkin's disease as related to its pathological picture. Cancer 1966; 19:317.</a></li><li><a class="nounderline abstract_t">Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26:1063.</a></li><li><a class="nounderline abstract_t">Strickler JG, Michie SA, Warnke RA, Dorfman RF. The "syncytial variant" of nodular sclerosing Hodgkin's disease. Am J Surg Pathol 1986; 10:470.</a></li><li><a class="nounderline abstract_t">Ashton-Key M, Thorpe PA, Allen JP, Isaacson PG. Follicular Hodgkin's disease. Am J Surg Pathol 1995; 19:1294.</a></li><li><a class="nounderline abstract_t">Sextro M, Diehl V, Franklin J, et al. Lymphocyte predominant Hodgkin's disease--a workshop report. European Task Force on Lymphoma. Ann Oncol 1996; 7 Suppl 4:61.</a></li><li><a class="nounderline abstract_t">Klimm B, Franklin J, Stein H, et al. Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol 2011; 29:3914.</a></li><li><a class="nounderline abstract_t">Neiman RS, Rosen PJ, Lukes RJ. Lymphocyte-depletion Hodgkin's disease. A clinicopathological entity. N Engl J Med 1973; 288:751.</a></li><li><a class="nounderline abstract_t">Leoncini L, Del Vecchio MT, Kraft R, et al. Hodgkin's disease and CD30-positive anaplastic large cell lymphomas--a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study. Am J Pathol 1990; 137:1047.</a></li><li><a class="nounderline abstract_t">Stein H, Herbst H, Anagnostopoulos I, et al. The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma. Ann Oncol 1991; 2 Suppl 2:33.</a></li><li><a class="nounderline abstract_t">Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010; 34:405.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Vassallo J, Lamant L, Brugieres L, et al. ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: report of 10 cases. Am J Surg Pathol 2006; 30:223.</a></li><li><a class="nounderline abstract_t">Bakshi NA, Finn WG, Schnitzer B, et al. Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma. Arch Pathol Lab Med 2007; 131:742.</a></li><li><a class="nounderline abstract_t">Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005; 29:1411.</a></li><li><a class="nounderline abstract_t">García JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histopathology 2005; 47:101.</a></li><li><a class="nounderline abstract_t">Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood 2015; 125:33.</a></li></ol></div><div id="topicVersionRevision">Topic 4688 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009944" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8443755" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8443755" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Natural history of Hodgkin's disease as related to staging</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14453744" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The radical radiotherapy of regionally localized Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5947346" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evidence for an orderly progression in the spread of Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113753" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7824016" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Images in clinical medicine. Cyclic fever in Hodgkin's disease (Pel-Ebstein fever)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4052959" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reevaluation of prognostic significance of symptoms in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4052959" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reevaluation of prognostic significance of symptoms in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6613116" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Alcohol-related pain and Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4744588" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Staging laparotomy and splenectomy in Hodgkin's disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8767104" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hodgkin's disease presenting as a cholestatic febrile illness: incidence and main characteristics in a series of 421 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10503847" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7547410" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16777693" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Skin involvement in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3653373" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The value of staging bone marrow trephine biopsy in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406078" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15536150" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150698" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24351400" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634503" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : CNS involvement in Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17416864" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hodgkin's lymphoma involving the CNS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686050" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Primary intracerebral Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591379" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : CNS Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9119979" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9678507" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407576" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9525818" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Chorea as a paraneoplastic complication of Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222201" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A case of Hodgkin's lymphoma producing neuromyotonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8738928" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Paraneoplastic limbic encephalitis in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7932460" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of lymphoma on the peripheral nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158207" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Subacute sensory neuropathy associated with Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2098300" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Stiff-man syndrome in a patient with Hodgkin's disease. An unusual paraneoplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339498" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Spectrum of paraneoplastic disease associated with lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705493" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510541" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Glomerular lesions in lymphomas and leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6835286" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1983. A 24-year-old man with cervical lymphadenopathy and the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8364192" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649225" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hypercalcemia and vitamin D metabolism in Hodgkin's disease. Is there an underlying immunoregulatory relationship?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8846146" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immune thrombocytopenia and hemolytic anemia associated with Hodgkin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1780074" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Coombs-positive hemolytic anemia in Hodgkin's disease: case presentation and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8688671" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Eosinophilia in Hodgkin's disease: a role for interleukin 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194423" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113771" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1716042" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1656757" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400691" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23305738" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29351987" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7530508" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7507734" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17536082" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879220" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9033270" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1433367" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Chromosomal abnormalities in patients with Hodgkin's disease: evidence for frequent involvement of the 14q chromosomal region but infrequent bcl-2 gene rearrangement in Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17418962" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8289502" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cytogenetic findings and results of combined immunophenotyping and karyotyping in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7632954" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7937902" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The Reed-Sternberg cells of Hodgkin disease are clonal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628145" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069084" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637283" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Rare occurrence of classical Hodgkin's disease as a T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25488972" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29650799" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29449275" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380639" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22469134" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29340061" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22955914" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369535" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11154228" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256685" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263788" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588891" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881301" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393731" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12208876" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11313274" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830455" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781246" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145210" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Natural history of Hodgkin's disease as related to its pathological picture</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5947336" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The pathology and nomenclature of Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2425645" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The "syncytial variant" of nodular sclerosing Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573692" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Follicular Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8836412" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Lymphocyte predominant Hodgkin's disease--a workshop report. European Task Force on Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911729" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4688713" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Lymphocyte-depletion Hodgkin's disease. A clinicopathological entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2173409" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hodgkin's disease and CD30-positive anaplastic large cell lymphomas--a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1646624" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20154586" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434897" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: report of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488159" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16224207" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982329" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Large B-cell lymphoma with Hodgkin's features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25499450" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
